top of page

USFDA Guidance: Photobiomodulation (PBM) Devices & Premarket Notification [510(k)] Submissions

Writer's picture: Sharan MuruganSharan Murugan

Recently (12-January-2023) the US Food and Drug Administration (FDA) relaeased draft guidance on "Photobiomodulation (PBM) Devices - Premarket Notification [510(k)] Submissions".


The term “photobiomodulation” is defined as the application of light at an irradiance that does not induce heating with the goal of altering biological activity especially which are intended for use in applications such as aesthetics, dermatology, and other general indications.

This draft guidance outlines its recommendations for non-clinical testing, clinical studies, and labeling for devices that support photobiomodulation (PBM), or low-level light therapy (LLLT).


Some light-emitting products that are intended for only general wellness use and present a low risk to the safety of users and other persons, may not be within the scope of this guidance.


The mechanism of actions for PBM for different clinical indications is not fully understood whereas the outcomes are dependent on many factors such as wavelength of light, fluence, irradiance, pulsing parameters, and beam spot size.


This guidance applies to class II PBM medical devices and also applies to the PBM component of devices that combine a PBM device with another device(s) (e.g., electrostimulation source, mechanical massager, or ultrasound).


The recommendations reflect current review practices and are intended to promote consistency and facilitate efficient review of PBM device submissions.


Click this LINK, to know more in detail about the Photobiomodulation & Premarket Submission Recommendations.

Comments


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page